Patents by Inventor Susan E. Lappe

Susan E. Lappe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20220403052
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: January 28, 2022
    Publication date: December 22, 2022
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Single-Chain Trail-Receptor Agonist Proteins
    Publication number: 20210040178
    Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: August 14, 2020
    Publication date: February 11, 2021
    Inventors: Fritz G. Buchanan, Christian Gieffers, Oliver Hill, Susan E. Lappe, Darren C. Phillips, Meinholf Thiemann
  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20190031783
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: March 7, 2018
    Publication date: January 31, 2019
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Single-Chain Trail-Receptor Agonist Proteins
    Publication number: 20180222962
    Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: February 2, 2018
    Publication date: August 9, 2018
    Inventors: Fritz G. Buchanan, Christian Gieffers, Oliver Hill, Susan E. Lappe, Darren C. Phillips, Meinholf Thiemann
  • Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
    Patent number: 9944720
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 17, 2018
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Single-chain trail-receptor agonist proteins
    Patent number: 9908927
    Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: March 6, 2018
    Assignees: AbbVie Inc., Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Fritz G. Buchanan, Darren C. Phillips, Susan E. Lappe
  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20160122439
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: September 4, 2015
    Publication date: May 5, 2016
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS
    Publication number: 20150337027
    Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: April 23, 2015
    Publication date: November 26, 2015
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Fritz G. Buchanan, Darren C. Phillips, Susan E. Lappe
  • Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
    Patent number: 9163093
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 20, 2015
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
    Patent number: 9045551
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: June 2, 2015
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20140348835
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: June 11, 2014
    Publication date: November 27, 2014
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20140134172
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: October 31, 2013
    Publication date: May 15, 2014
    Applicant: ABBVIE INC.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao